Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing

What this Trial Is About

Researchers are studying people with presumed intraocular infections, including various types of uveitis and post-operative endophthalmitis, to compare two testing methods. The trial evaluates whether metagenomic deep sequencing (MDS) of ocular fluid or tissue can improve patient outcomes compared to standard diagnostic tests like Gram stain, cultures, and PCR. The goal is to see if MDS helps guide appropriate therapy and improves clinical results. Participants will be randomly assigned to one of two groups. One group receives standard of care testing, while the other group receives both standard testing and MDS testing. All patients will be treated based on standard care, with the addition of MDS results for the experimental group. The trial includes follow-up visits at week 2, between weeks 3 and 6 (randomization visit), and 4 weeks after randomization. During the study, researchers will measure if patients receive the correct therapy and their clinical improvement four weeks after randomization. They will also assess provider certainty, patient quality of life, infection status, and provider quality of care. Participants can expect eye exams, testing of ocular samples, and questionnaires during scheduled visits. The total duration of participation spans several weeks with close monitoring.

Ocular Pathogen and Transcriptome Investigation Using Comprehensive Sequencing